In a recently published case report, we explore the successful treatment of myasthenia gravis (MG) following long COVID in a 71-year-old patient, using HemoClear gravity-driven plasma exchange.
Despite initial deterioration and resistance to standard therapy, the patient showed marked clinical improvement following low-volume plasmapheresis using HemoClear’s straightforward and cost-effective gravity-driven microfiltration technology.
This case highlights the value of accessible innovations like HemoClear in managing complex post-COVID autoimmune conditions, where conventional treatments may be unavailable.
Read the full case: https://bit.ly/3Hxwr7m
Efficacy of Plasma Exchange in Myasthenia Gravis Following Long COVID in a Resource-Limited Context
